Georgia Cancer Research Fund
Your tax filing can help fight cancer
When you prepare your next Georgia income tax return – please consider adding a few dollars to Line 33 to support the Georgia Cancer Research Fund.
Those funds go straight to researchers who are hard at work in Georgia labs finding new ways to fight cancer. They’re developing new treatments and new tools for diagnosis – and they’re grateful for Georgians who choose to support them.
It’s easy to do: Just enter any amount (over $1) on Line 33 of Georgia’s Income Tax Form 500. The state’s Department of Revenue will factor this amount into your tax refund or liability – so you don’t have to write a separate check or take any other action.
Won’t you join us? Download the form here.
Collaborative Cancer Research Seed Grant
The 3rd annual Collaborative Cancer Research Grant was gifted to two teams for FY25. $100,000 has been awarded to principal investigators Claire A. Spears, PhD, Associate Professor at Georgia State University’s School of Public Health, and Martha S. Tingen, PhD, RN, FAAN, Professor of Medicine at the Augusta University’s Georgia Prevention Institute and Georgia Cancer Center. The second $100,000 award goes to PIs Jin Xie, PhD, Professor in the Department of Chemistry at the University of Georgia and Yong Teng, PhD, MSc, Associate Professor in the Department of Hematology and Medical Oncology at Emory University’s Winship Cancer Institute. Read more >>
The FY24 and 2nd annual Collaborative Cancer Research Grant was awarded to Dr. Susan N. Thomas, Woodruff Associate Professor at Georgia Tech and Dr. Sarwish Rafiq, Assistant Professor at Emory University. The grant funded research titled, "Engineering super migratory CAR T cells for PDAC immunotherapy." Read more >>
The FY23 and very first grant of its kind from the Georgia Cancer Research Fund was awarded to Jack Arbiser, PhD of the Emory University School of Medicine and Lisa Flowers, MD, MPH of the Georgia Cancer Center for Excellence at Grady. The grant funded a clinical trial titled, "Phase I Dose Escalation Study of the Use of ACU-D1, a Topical Proteasome Inhibitor in HPV associate Vulvar and Perianal Lesion in People with HIV." Read more >>
Last Updated: 5/10/2024 11:38:04 AM